Friday, March 10, 2023 Daily Archives

Accelerating Antibody Characterization and AAV Analytics Using Next Gen Biolayer Interferometry (BLI)

by

This webcast features: Benjamin Osborne, PhD, Senior Application Scientist, Gator Bio. Efficient kinetics and epitope binning studies are critical to biotherapeutics development. Biolayer Interferometry (BLI) is an exceptional tool to easily and quickly obtain results. In the face of modern throughput challenges, BLI instruments were historically modified to monitor multiple wells per spectrometer, resulting in poor kinetics measurements. To address these shortcomings, Gator Bio has launched the Gator Pro that enables 32 high frequency parallel measurements, alongside a family of…

March 10, 2023

MA plant to strengthen Oligo Factory in $10bn+ tides market

by

CDMO Oligo Factory has increased its oligonucleotide synthesis capability 12-fold through the opening of a 13,000 square-foot facility in Holliston, Massachusetts. The facility – which opened its doors earlier this month and represents over $1 million in customized hardware and unique buildout – consists of bench space, offices, and labs for Oligo Factory’s next generation of synthesizers, and significantly ups its manufacturing capacity. Oligo Factory delivers oligos for several markets, including functional genomics, diagnostics, and therapeutics. The growing demand drove…

March 10, 2023

Sandoz lines up $400m biosimilar production plant in Slovenia

by

Novartis’s soon-to-be independent Sandoz division has signed a Memorandum of Understanding (MOU) to build a plant in Lendava to support its biosimilar products. The deal, announced yesterday, saw Sandoz pledge at least $400 million into the new plant, work on which is expected to begin later this year. “The plan is to produce biosimilars at the plant,” Sandoz spokesperson Chris Lewis told this publication, with the center supporting both the firm’s current portfolio and future pipeline. Full operations are planned…

March 10, 2023

Danaher partners with UPenn to advance cell therapy tech

by

The partnership aims to develop technologies to tackle manufacturing bottlenecks in the delivery of engineered cell products. The multi-year partnership between Danaher Corporation and the University of Pennsylvania (UPenn) looks to improve the consistency of clinical outcomes for patients by addressing manufacturing challenges associated with cellular immunotherapies. Both parties said the collaboration is driven by the scale of clinical development identified in the CAR-T cell therapy space. There are six US Food and Drug Administration (FDA) approved CAR-T cell therapies:…

March 10, 2023